Prosecution Insights
Last updated: April 19, 2026
Application No. 18/255,119

IODOTYROSINE DERIVATIVES AND PROCESS FOR PREPARING IODOTYROSINE DERIVATIVES

Non-Final OA §103
Filed
May 31, 2023
Examiner
SAWYER, JENNIFER C
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH
OA Round
1 (Non-Final)
69%
Grant Probability
Favorable
1-2
OA Rounds
2y 9m
To Grant
58%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allow Rate
375 granted / 545 resolved
+8.8% vs TC avg
Minimal -11% lift
Without
With
+-10.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
45 currently pending
Career history
590
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
43.9%
+3.9% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
24.7%
-15.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 545 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action This office action is in response to applicant’s communication filed on 12/10/25. Claims 16-30 are pending in this application. Applicant's election of Group 1, claims 16-23, without traverse, in the reply filed on 12/25/25 is acknowledged. Thus claims 24-30 are withdrawn. Applicant’s election of the following compound is acknowledged herewith: PNG media_image1.png 60 584 media_image1.png Greyscale Claim 23 is withdrawn and being non-readable on the elected species. As a result, claims 16-22 are being examined in this Office Action. Priority The applicant claims benefit as follows: PNG media_image2.png 166 460 media_image2.png Greyscale Claim Rejections – 35 USC 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 1 03(a) are summarized as follows: Applicant Claims Determining the scope and contents of the prior art. Ascertaining the differences between the prior art and the claims at issue, and resolving the level of ordinary skill in the pertinent art. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 16-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Giroud et al. (J. Med. Chem., 2018, 61, 3370), in view of Greene’s Protective Groups in Organic Synthesis (4th Ed., Wuts and Greene, 2007, John Wiley). Determination of the Scope and Content of the Prior Art (MPEP §2141.01) Giroud et al. exemplifies the following compound, which corresponds to applicant’s compound I as follows: SG = t-butyl (Boc) protecting group A = R1 – O – R2 R1 = ethylene R2 = methyl Halogen is Chlorine at the 3 position PNG media_image3.png 130 110 media_image3.png Greyscale PNG media_image4.png 30 124 media_image4.png Greyscale Ascertainment of the Difference Between Scope the Prior Art and the Claims (MPEP §2141.012) Giroud et al. is deficient in the sense that it does not teach applicant’s particular iodine substitution, 9-fluorenylmethyl (Fmoc) protecting group and methylene linker. Instead Giroud et al. teaches chlorine substitution, a t-butyl (Boc) protecting group and an ethylene linker. Finding of Prima Facie Obviousness Rationale and Motivation (MPEP §2142-2143) However, it would be prima facie obvious to one of ordinary skill in the art at the time of the invention, to substitute a different halogen, an ethylene linker for a methylene linker and use the Boc protecting group instead of a FMOC protecting group on the tyrosine derivative. Both iodine and chlorine are halogens and are commonly employed as isosteric replacements for each other. Further, an ethylene linker (two CH2 groups) versus a methylene linker (one CH2 group) are homologous. Thus it would be obvious to substitute an methylene linker with an ethylene linker on the tyrosine derivative. Additionally, both the t-butyl (Boc) and the 9-fluorenylmethyl (Fmoc) protecting groups are commonly used carbamate protecting groups for amino acids and amines. Greene’s Protective Groups in Organic Synthesis teaches the equivalency of the t-butyl (Boc) and the 9-fluorenylmethyl (Fmoc) protecting groups for the nitrogen amine in amino acids. (see page 707, second paragraph) Note that an express suggestion to substitute one equivalent component or process for another is not necessary to render such substitution obvious. In re Fout, 675 F.2d 297, 213 USPQ 532 (CCPA 1982). Thus the claims are obvious because it would have been obvious to try alternative isosteres, homologs and equivalent protecting groups, with a reasonable expectation of success. Thus the skilled artisan would have had reason to try these replacements, with the reasonable expectation that it would be successful. Synthesizing compounds with isosteres, homologs and equivalent protecting groups is not a method of innovation but of ordinary skill and common sense. Absent any showing of unusual and/or unexpected results over Applicant's particular tyrosine derivative, the art obtains the same effect on the compound' s efficacy and utility. The expected result would be the synthesis of tyrosine derivatives, for the chemical industry. “Structural relationships may provide the requisite motivation or suggestion to modify known compounds to obtain new compounds. For example, a prior art compound may suggest its homolog because homologs often have similar properties and therefore chemists of ordinary skill would ordinarily contemplate making them to try to obtain compounds with improved properties.” (see MPEP § 2144.08c). In addition, homologs are generally so structurally similar that “without more” such structural similarity could give rise to prima facie obviousness (see In re Wilder, 563 F.2d 457, 195 USPQ 426). The MPEP 2144.09 states “Compounds which are… homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Cho Sawyer whose telephone number is (571) 270 1690. The examiner can normally be reached on Monday-Friday 9 AM - 6 PM PST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Renee Claytor can be reached on (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-274-1690. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Jennifer Cho Sawyer Patent Examiner Art Unit: 1691 /RENEE CLAYTOR/Supervisory Patent Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

May 31, 2023
Application Filed
Jan 24, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12552735
PROCESS FOR THE SYNTHESIS OF TWIN-TAIL TRIAMINES
2y 5m to grant Granted Feb 17, 2026
Patent 12552753
Methods and Compositions for Targeting Tregs using CCR8 Inhibitors
2y 5m to grant Granted Feb 17, 2026
Patent 12528758
PRODUCTION OF AROMATIC ACIDS AND PHENOLICS
2y 5m to grant Granted Jan 20, 2026
Patent 12528765
CONTINUOUS SYNTHESIS METHOD OF 2-ACETAMIDO-5-NITROANISOLE
2y 5m to grant Granted Jan 20, 2026
Patent 12509417
ENANTIOSELECTIVE PROCESS
2y 5m to grant Granted Dec 30, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
69%
Grant Probability
58%
With Interview (-10.6%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 545 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month